Lamivudine News and Research

RSS

New injectable solution could help manage HIV unlike any current treatment methods

A new injectable solution that self-assembles into a gel under the right conditions could help manage HIV unlike any currently available methods, researchers have found.

25 Sep 2023

Child-friendly HIV drug could improve treatment outcomes

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human immunodeficiency virus (HIV).

2 Aug 2023

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.

23 Feb 2023

Case report describes clinical manifestation of monkeypox, SARS-CoV-2, and HIV coinfection

Scientists have recently presented the first documented case of coinfection with monkeypox virus, SARS-CoV-2, and HIV.

23 Aug 2022

Clinical presentation of monkeypox infection in two Israeli males

Researchers described the symptomatology and clinical manifestations of monkeypox infections among two Israeli patients.

12 Jul 2022

Antiretroviral drug used to treat HIV ameliorates cognitive deficits in mouse model of Down syndrome

Lamivudine, a commonly-used antiretroviral drug for treating HIV, improves cognition in a mouse model of Down syndrome, according to the findings of a joint new study by researchers at the Centre for Genomic Regulation (CRG) and the IrsiCaixa AIDS Research Institute, a center jointly promoted by the "la Caixa" Foundation and the Department of Health of the Generalitat de Catalunya.

28 Jun 2022

HIV drug stops disease progression in 25% of patients with fourth-line metastatic colorectal cancer

New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer.

5 Apr 2022

Use of antiviral and antiretroviral medication could have detrimental impact on crops

The increased global use of antiviral and antiretroviral medication could have a detrimental impact on crops and potentially heighten resistance to their effects, new research has suggested.

29 Jan 2021

Drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests.

23 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today.

11 Mar 2020

FSU discovery could open the door to new treatment options for HIV, hepatitis B

A discovery by Florida State University College of Medicine researchers is expected to open the door for new and more potent treatment options for many of the more than 36 million people worldwide infected with the HIV virus and for others chronically ill with hepatitis B.

8 Jan 2020

FDA approves two-drug complete regimen for previously untreated HIV-infected adults

The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.

9 Apr 2019

Antiviral treatment improves survival for kidney transplant recipients infected with HBV or HCV

Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B or hepatitis C experienced poor outcomes.

15 Mar 2019

Scientists find abnormal gene copying in fruit fly models of tauopathies

It sounds like science fiction: Nefarious genes clone themselves and settle their rogue copies in distant outposts of the galaxy (namely, our DNA), causing disease.

24 Jul 2018

Study reveals lack of access to essential medicines in India

Research has revealed the shocking lack of access to essential medicines in India, despite thousands being approved in an attempt to generate wider availability.

27 Jan 2018

NIH launches large study to compare treatments for pregnant women with HIV

The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants.

24 Jan 2018

Scientists create stem cell-based model of rare inherited neurological condition

An international team of scientists, led by University of California San Diego School of Medicine researchers, has created a human stem cell-based model of a rare, but devastating, inherited neurological autoimmune condition called Aicardi-Goutieres Syndrome (AGS).

11 Aug 2017

Injectable ART may have same effectiveness as standard oral treatments

Antiretroviral therapy (ART) intramuscularly administered may have the same effectiveness as current oral treatments.

3 Aug 2017

Dual therapy effective as second-line treatment for patients infected by HIV with multiple mutations

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa (Cameroon, Burkina Faso, and Senegal), shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations.

29 May 2017